// App-Quantinova.ai

173 : Comparative effectiveness of secukinumab and golimumab in ankylosing spondylitis assessed by matching-adjusted indirect comparison using pivotal phase III clinical trial data

Researchers

Presenter

  • Hasan Tahir

Principal Investigators

  • Walter Maksymowych

  • Ernest Choy

  • Yusuf Yazici

  • Jessica Walsh

  • Howard Thom

  • Chrysostomos Kalyvas

  • Todd Fox

  • Kunal Gandi

  • Steffen Jugl

Medical Centers

  • Rheumatology, Barts Health NHS Trust, London, UNITED KINGDOM

  • Medicine, University of Alberta, Edmonton, AB, CANADA

  • Division of Infection and Immunity, Cardiff University, Cardiff, UNITED KINGDOM

  • Internal Medicine, University of Utah, Salt Lake City, UT

  • Bristol Medical School: Population Health Sciences, University of Bristol, Bristol, UNITED KINGDOM

  • Real World Strategy and Analytics, Mapi group, Houten, NETHERLANDS

  • Immunology & Dermatology Franchise, Novartis Pharma AG, Basel, SWITZERLAND

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

Locations

  • United Kingdom

  • Canada

  • United States

  • Netherlands

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

  • golimumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Multinational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved